✦ LIBER ✦

Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: Final 3-year results of the SPIRIT clinical trials program (Clinical evaluation of the Xience v everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions)

✍ Scribed by Dangas, George D. (author);Serruys, Patrick W. (author);Kereiakes, Dean J. (author);Hermiller, James (author);Rizvi, Ali (author);Newman, William (author);Sudhir, Krishnankutty (author);Smith, Robert S. (author);Cao, Sherry (author);Theodoropoulos, Kleanthis (author);Cutlip, Donald E. (author);Lansky, Alexandra J. (author);Stone, Gregg W. (author)

Book ID: 122030242
Publisher: American College of Cardiology
Year: 2013
Tongue: English
Weight: 522 KB
Volume: 6
Category: Article
ISSN: 1936-8798
DOI: 10.1016/j.jcin.2013.05.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Meta-analysis of everolimus-eluting vers

Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: Final 3-year results of the SPIRIT clinical trials program (Clinical evaluation of the Xience v everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions)

✍ Dangas, George D. (author);Serruys, Patrick W. (author);Kereiakes, Dean J. (auth 📂 Article 📅 2013 🏛 American College of Cardiology 🌐 English ⚖ 522 KB

Randomized Comparison of Everolimus-Elut

Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: Two-Year Clinical Follow-Up From the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SPIRIT) III Trial

✍ Stone, G. W.; Midei, M.; Newman, W.; Sanz, M.; Hermiller, J. B.; Williams, J.; F 📂 Article 📅 2009 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 436 KB

Comparison of Everolimus-Eluting and Pac

Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients Undergoing Multilesion and Multivessel Intervention: The SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials

✍ Dean J. Kereiakes; Krishnankutty Sudhir; James B. Hermiller; Paul C. Gordon; Joa 📂 Article 📅 2010 🏛 American College of Cardiology 🌐 English ⚖ 939 KB

SPIRIT II STUDY: EVALUATION OF THE XIENC

SPIRIT II STUDY: EVALUATION OF THE XIENCE V EVEROLIMUS ELUTING CORONARY STENT IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS

✍ Onuma, Yoshinobu; Serruys, Patrick W.; the SPIRIT II Investigators, ; Center, Th 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 60 KB

SPIRIT II STUDY: EVALUATION OF THE XIENC

SPIRIT II STUDY: EVALUATION OF THE XIENCE V EVEROLIMUS ELUTING CORONARY STENT IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS: 5-YEAR RESULTS

✍ Onuma, Yoshinobu; Serruys, Patrick W. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 118 KB

Four-year clinical follow-up of the XIEN

Four-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT II trial

✍ Scot Garg; Patrick W. Serruys; Karine Miquel-Hebert; on behalf of the SPIRIT II 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB 👁 2 views

## Abstract This report describes the 4‐year clinical outcomes of the SPIRIT II study, which randomized 300 patients to treatment with the XIENCE V everolimus‐eluting stent (EES), or the TAXUS paclitaxel‐eluting stent. At 4‐year clinical follow‐up, which was available in 256 (85.3%) patients, treat